Jefferies Financial Group Inc. Arbutus Biopharma Corp Transaction History

Jefferies Financial Group Inc.

  • $10.2 Billion
  • Q1 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$2.24 - $3.06 $592,347 - $809,189
264,441 New
264,441 $608,000

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $489M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email